Mineralys Therapeutics, Inc. Profile Avatar - Palmy Investing

Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administ…

Biotechnology
US, Radnor [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of MLYS's Analysis
CIK: 1933414 CUSIP: 603170101 ISIN: US6031701013 LEI: - UEI: -
Secondary Listings
MLYS has no secondary listings inside our databases.